20265-38-7

Basic information

• Product Name: 2-Methoxypyridin-3-amine
• Synonyms: TIMTEC-BB SBB005483;BUTTPARK 37\08-36;2-METHOXYPYRIDIN-3-AMINE;2-METHOXY-PYRIDIN-3-YLAMINE;3-AMINO-2-METHOXYPYRIDINE;2-Methoxy-3-aminopyridine;2-Methoxypyridine-3-amine;3-AMINO-2-METHOXYPYRIDINE 98+%
• CAS NO: 20265-38-7
• Molecular Formula: C₆H₈N₂O
• Molecular Weight: 124.14
• EINECS: -0
• Product Categories: Pyridine;pharmacetical;Pyridine series;Pyridines;Amines
• Mol File: 20265-38-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 67 °C
• Boiling Point: 118°C/13mmHg(lit.)
• Flash Point: 99.3 °C
• Appearance: /
• Density: 1.139 g/cm³
• Vapor Pressure: 0.0377mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: 4.33±0.10(Predicted)
• CAS DataBase Reference: 2-Methoxypyridin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methoxypyridin-3-amine(20265-38-7)
• EPA Substance Registry System: 2-Methoxypyridin-3-amine(20265-38-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-41-37/38-22
• Safety Statements: 26-36/37/39-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 20265-38-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H8N2O/c1-9-6-5(7)3-2-4-8-6/h2-4H,7H2,1H3

Upstream product

• 6298-19-7 2-chloro-3-aminopyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 20265-35-4 2-methoxy-3-nitropyridine 
• 462-08-8 pyridin-3-ylamine 
• 124-41-4 sodium methylate 
• 7145-28-0 2-methoxy-3-pyridinecarboxamide 

Downstream Products

• 161117-83-5 3-(N-tert-butoxycarbonylamino)-2-methoxypyridine 
• 6298-19-7 2-chloro-3-aminopyridine 
• 259684-36-1 1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 259684-39-4 1,6-dihydro-3-(phenylthio)-7H-pyrrolo[2,3-c]pyridin-7-one 
• 259684-48-5 2-(3-amino-2-methoxypyridin-4-yl)-2-(phenylthio)acetaldehyde dimethylacetal 
• 1173983-36-2 ethyl 4-{4-chloro-7-(1-ethylpropyl)-2-[(2-methoxypyridin-3-yl)amino]-1H-benzimidazol-1-yl}butanoate 
• 1173983-37-3 ethyl 4-{4-chloro-7-(1-ethylpropyl)-2-[(2-hydroxypyridin-3-yl)amino]-1H-benzimidazol-1-yl}butanoate 
• 160590-38-5 3-hydrazinyl-2-methoxypyridine 
• 1020085-51-1 C₉H₁₀ClNO₂ 

Relevant articles and documents

Propionic Acid Derivatives and Methods of Use Thereof

Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

2-PYRIDONE COMPOUNDS

A 2-pyridone compound represented by the formula [1]: {wherein in the formula [1], the ring represented by A represents a benzene ring or a pyridine ring, X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, and W represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)}, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.

Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder

A series of novel cyanoguanidine derivatives was designed and synthesized. Condensation of N-(1-benzotriazol-1-yl-2,2-dichloropropyl)-substituted benzamides with N-(substituted-pyridin-3-yl)-N′-cyanoguanidines furnished N-{2,2-dichloro-1-[N′-(substituted-pyridin-3-yl)-N′-cyanoguanidino] propyl}-substituted benzamide derivatives. These agents were glyburide-reversible potassium channel openers and hyperpolarized human bladder cells as assessed by the FLIPR membrane potential dye (KATP-FMP). These compounds were also potent full agonists in relaxing electrically stimulated pig bladder strips, an in vitro model of overactive bladder. The most active compound 9 was evaluated for in vivo efficacy and selectivity in a pig model of bladder instability. Preliminary pharmacokinetic studies in dog demonstrated excellent oral bioavailability and a t1/2 of 15 h. The synthesis, SAR studies, and biological properties of these agents are discussed.